Abstract | AIMS: METHODS AND RESULTS: Consecutive STEMI patients meeting the inclusion criteria and undergoing PPCI were enrolled. The primary endpoint was major adverse cardiac events ( MACE) at 30 days, defined as the composite of cardiac death, myocardial infarction (Q wave and non-Q wave) or target lesion revascularization (PCI or coronary artery bypass graft). Secondary endpoints included device success, lesion success, and postprocedural reperfusion outcomes: thrombolysis in myocardial infarction (TIMI) flow and ST-segment elevation resolution (STR). A total of 97 patients (62 years, 77% men) were included. Symptom to cathlab time was 238 min. Device and lesion success were 100%. Final TIMI-3 flow was achieved in 91.8%, and STR > 50% in 87% of the patients. MACE at 30 days was 2.2%, which consisted of one case each of target vessel (TV)- myocardial infarction (MI), and non-TV-MI. CONCLUSIONS: The use of the MGuard Prime EPS stent is feasible and safe and could be also effective in achieving myocardial reperfusion in STEMI patients undergoing PPCI.
|
Authors | Giovanni Amoroso, Nicola S Vos, Jan A S Van der Heyden, Renė J van der Schaaf, Mark S Patterson, Maarten A Vink, Jean-Paul Herrman, Ton Slagboom |
Journal | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
(Catheter Cardiovasc Interv)
Vol. 86 Suppl 1
Pg. S28-33
(Oct 2015)
ISSN: 1522-726X [Electronic] United States |
PMID | 25754236
(Publication Type: Journal Article, Observational Study)
|
Copyright | © 2015 Wiley Periodicals, Inc. |
Topics |
- Coronary Angiography
- Electrocardiography
- Embolic Protection Devices
- Embolism
(prevention & control)
- Follow-Up Studies
- Humans
- Myocardial Infarction
(diagnostic imaging, surgery)
- Percutaneous Coronary Intervention
(methods)
- Postoperative Complications
(prevention & control)
- Product Surveillance, Postmarketing
(methods)
- Prospective Studies
- Prosthesis Design
- Stents
- Treatment Outcome
|